BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years

Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the weekend, while separately announcing that it was returning Immatics’ bispecific T cell engager.